<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The major clinical problem of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) is the aortic root <z:hpo ids='HP_0002617'>aneurysm</z:hpo>, with risk of dissection when the root diameter approximates 5 cm </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, a key molecule, transforming growth factor-beta (TGF-beta), normally bound to the extracellular matrix, is free and activated </plain></SENT>
<SENT sid="2" pm="."><plain>In an experimental setting, TGF-beta blockade prevents the aortic root structural damage and <z:mpath ids='MPATH_66'>dilatation</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>The angiotensin receptor 1 blockers (sartanics) exert an anti-TGF-beta effect; trials are now ongoing for evaluating the effect of <z:chebi fb="0" ids="6541">losartan</z:chebi> compared with atenolol in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="35530">beta-Adrenergic blockers</z:chebi> are the drugs most commonly used in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The third-generation <z:chebi fb="0" ids="35530">beta-adrenergic blocker</z:chebi> nebivolol retains the <z:chebi fb="0" ids="35530">beta-adrenergic blocker</z:chebi> effects on heart rate and further exerts antistiffness effects, typically increased in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>METHODS: The open-label phase III study will include 291 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and proven FBN1 gene mutations, with aortic root dilation (z-score &gt; or =2.5) </plain></SENT>
<SENT sid="7" pm="."><plain>The patients will be randomized to nebivolol, <z:chebi fb="0" ids="6541">losartan</z:chebi> and the combination of the two drugs </plain></SENT>
<SENT sid="8" pm="."><plain>The primary end point is the comparative evaluation of the effects of <z:chebi fb="0" ids="6541">losartan</z:chebi>, nebivolol and the association of both on the progression of aortic root growth rate </plain></SENT>
<SENT sid="9" pm="."><plain>Secondary end points include the pharmacokinetics of the two drugs, comparative evaluation of serum levels of total and active TGF-beta, quantitative assessment of the expression of the mutated gene (FBN1, both 5' and 3'), pharmacogenetic bases of drug responsiveness </plain></SENT>
<SENT sid="10" pm="."><plain>The quality of life evaluation in the three groups will be assessed </plain></SENT>
<SENT sid="11" pm="."><plain>Statistical evaluation includes an interim analysis at month 24 and conclusive analyses at month 48 </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: The present study will add information about pharmacological therapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, supporting the new application of angiotensin receptor 1 blockers and finding <z:chebi fb="0" ids="35530">beta-adrenergic blockers</z:chebi> that may give more specific effects </plain></SENT>
<SENT sid="13" pm="."><plain>Moreover, the study will further deepen understanding of the pathogenetic mechanisms that are active in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> through the pharmacogenomic and transcriptomic mechanisms that may explain <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> phenotype variability </plain></SENT>
</text></document>